Henry Ford Health has filed a lawsuit against CVS Health alleging fraudulent reimbursement practices tied to the federal 340B drug discount program, claiming losses of more than $29 million. The complaint accuses CVS of manipulating pricing and engaging in retaliatory behavior, adding to a series of disputes between large health systems and pharmacy operators over 340B program administration. The case extends a pattern of litigation in the 340B space and could affect CVS Health's relationships with health systems, its ability to retain 340B contracts, and future compliance costs. Investors may watch for any responses from CVS Health and whether the case influences broader discussions around contract terms, reimbursement models, or program oversight.
CVS Health CorpSued by Henry Ford Health over alleged fraudulent 340B program practices, risking financial losses, contract retention, and compliance costs.